{"nctId":"NCT00840086","briefTitle":"Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects","startDateStruct":{"date":"2009-04"},"conditions":["Congenital Bleeding Disorder","Haemophilia A"],"count":150,"armGroups":[{"label":"rFVIII","type":"EXPERIMENTAL","interventionNames":["Drug: turoctocog alfa"]}],"interventions":[{"name":"turoctocog alfa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male subjects with the diagnosis of severe (FVIII less than or equal to 1%) haemophilia A from age 12 (except for Israel where the age limit will be 18 for the first 10 subjects recruited in the trial) to 56 years having a weight of 10 to 120 kg\n* Documented history of at least 150 exposure days to any other FVIII products (prevention or treatment of bleeds)\n* No history of FVIII inhibitors greater than or equal to 0.6 BU/mL. The inhibitor should be measured regularly for at least the last 8 years or since the first treatment of haemophilia A\n* No detectable inhibitors to FVIII (greater than or equal to 0.6 BU/mL) (as assessed by a Central Laboratory at the time of screening)\n\nExclusion Criteria:\n\n* Congenital or acquired coagulation disorders other than haemophilia A\n* Creatinine levels 50% above normal level (as defined by central laboratory range)\n* Known or suspected allergy to trial product (N8) or related products","healthyVolunteers":false,"sex":"MALE","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU))","description":"The incidence rate of FVIII inhibitors was calculated by including all patients with inhibitors in the nominator and including all patients with a minimum 50 exposure plus any patients with less than 50 exposures but with inhibitors in denominator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Adverse Events (AEs)","description":"Adverse event was defined as events occurring after administration of trial product. Severe AEs: considerable interference with subject's daily activities, unacceptable. Moderate AEs: Marked symptoms, moderate interference with the patient's daily activities. Mild AEs: No or transient symptoms, no interference with the patient's daily activities. Serious AEs: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalization, persistent/significant disability/incapacity/congenital anomaly/birth defect.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"225","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":150},"commonTop":["Incorrect dose administered","Headache","Nasopharyngitis"]}}}